Natural Medicine Advisory Bulletin 13: Peaking in July
Reading Time: 8 minutes July 12th: NMAB Combined Subcommittee MeetingThe July 12th meeting of the combined subcommittee began with
Reading Time: 8 minutes July 12th: NMAB Combined Subcommittee MeetingThe July 12th meeting of the combined subcommittee began with
Reading Time: < 1 minute Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development
Reading Time: < 1 minute In this Issue Lykos Scales Back Investigator-Initiated Trials Program, Refers Some Researchers to PharmAla Lykos
Reading Time: 2 minutes Following Lykos Therapeutics’ receipt of a Complete Response Letter (CRL) from the FDA, which is effectively a rejection of
Reading Time: < 1 minute In this Issue Lykos CEO Provides AdComm Feedback to FDA Commissioner Cybin Plans to Fight
Reading Time: < 1 minute Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development
Reading Time: < 1 minute Following FDA’s refusal to approve Lykos Therapeutics’ MDMA-assisted therapy for PTSD New Drug Application (NDA), a key
Reading Time: 5 minutes Final rules from DOR’s Natural Medicine Division governing Natural Medicine Businesses come in at just
Reading Time: < 1 minute Following FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD New Drug Application (NDA), the
Reading Time: 2 minutes As I reported on Friday evening, Lykos looks set to appeal the FDA’s decision. The company said